An Open-label, Randomized, Single-dose, Two-way Crossover Study to Compare the Bioequivalence of Senaparib 10 mg Capsules Manufactured at Different Manufacturing Sites After Administration in Fasting State in Healthy Chinese Subjects
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Senaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors IMPACT Therapeutics
Most Recent Events
- 21 Jan 2025 New trial record